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Anxiety disorders are the most common psychiatric disorders. They are frequently treated
with benzodiazepines, which are fast acting highly effective anxiolytic agents. However,
their long-term use is impaired by tolerance development and abuse liability. In contrast,
antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are considered as
ﬁrst-line treatment but have a slow onset of action. Neurosteroids are powerful allosteric
modulators of GABAA and glutamate receptors. However, they also modulate sigma recep-
tors and they are modulated themselves by SSRIs. Both pre-clinical and clinical studies
have shown that neurosteroid homeostasis is altered in depression and anxiety disorders
and antidepressants may act in part through restoring neurosteroid disbalance. Moreover,
novel drugs interfering with neurosteroidogenesis such as ligands of the translocator pro-
tein (18 kDa) may represent an attractive pharmacological option for novel anxiolytics which
lack the unwarranted side effects of benzodiazepines. Thus, neurosteroids are important
endogenous neuromodulators for the physiology and pathophysiology of anxiety and they
may constitute a novel therapeutic approach in the treatment of these disorders.
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INTRODUCTION
Anxiety disorders are among the most common mental health
conditions, which cause signiﬁcant functional impairments, and
frequently turn into chronic clinical conditions (Nutt et al., 2002;
Kessler et al., 2005). Recent epidemiological ﬁndings suggest them
as the most frequent class of mental disorders with a high degree
of comorbidity with other medical and psychiatric conditions
(Kessler et al., 2005).
Currently six primary anxiety disorders are identiﬁed in DSM-
IV-R: panic disorder (characterized by recurrent panic attacks),
generalized anxiety disorder (characterized by frequent worrying)
posttraumatic stress disorder (the result of a traumatic experi-
ence), obsessive–compulsive disorder (characterized by repetitive
obsessions and the urge to perform speciﬁc acts or rituals) and
speciﬁc phobia (in which speciﬁc stimuli trigger fear and/or anxi-
ety). Both pharmacotherapy and psychotherapy are effective treat-
ments for anxiety disorders. First-line treatments are the selective
serotonin reuptake inhibitors (SSRIs) that display their anxi-
olytic effects after several weeks of treatment (Baldwin and Nair,
2005; Bandelow et al., 2008). On the other hand, benzodiazepines
(BDZs) are fast acting and effective antianxiety agents and themost
commonly used anxiolytic agents. Low levels of γ-aminobutyric
acid (GABA) have been attributed to the occurrence of anxiety
disorders such as panic disorder (Lydiard, 2003; Nemeroff, 2003).
Moreover, BDZs are potent positive allosteric modulators of the
GABAA receptors (Rudolph and Möhler, 2006). In addition, sigma
receptors (in particular sigma-1) and translocator protein (TSPO;
18 kDa) ligands have been identiﬁed as promising therapeutic
tools for the treatment of anxiety disorders (Costa et al., 1994;
Kulkarni and Dhir, 2009; Rupprecht et al., 2009; Taliani et al.,
2009).
The term “neurosteroids” (NS), a term introduced by Baulieu
(Baulieu and Robel, 1990; Paul and Purdy, 1992; Compagnone
and Mellon, 2000), indicates steroids that modulate the action
of the central nervous system (CNS), thereby regulating synap-
tic transmission at different targets (rapid non-genomic effect on
presynaptic receptors and long-term genomic action). The most
important effect of NS occur at the GABAA receptor, but NS may
exert various effects at the N -methyl-d-aspartate (NMDA), alpha-
amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA),
kainate, glycine, serotonin, sigma type-1, and nicotinic acetyl-
choline receptors (Rupprecht and Holsboer, 2001).
Thus, NS represent promising compounds modulating both
the pathophysiology and the pharmacotherapy of anxiety dis-
orders. Here, we provide a review of the different actions of
NS and discuss the evidence given by pre-clinical and clinical
data. The most extensively studied neurosteroid is the proges-
terone derivative 3α-hydroxysteroid-5α-pregnan-20-one (3α, 5α-
THP, allopregnanolone, Figure 1). In the brain, it is synthesized
from progesterone by the sequential action of two enzymes:
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FIGURE 1 | Biosynthetic pathway of 5α-dihydroprogesterone and 3α, 5α-tetrahydroprogesterone (3α, 5α-THP).The rate-limiting step is the cholesterol
translocation into the mitochondria by the mitochondrial translocator protein (18 kDa; TSPO). The ﬁgure shows the chemical structures of the main NS involved
in this pathway.
5α-reductase type I, which transforms progesterone into 5α-
dihydroprogestrerone (5α-DHP) and 3α-hydroxysteroid oxidore-
ductase (3α-HSD), which reduces 5α-DHP into 3α, 5α-THP in a
reversible manner (Dong et al., 2001).
SEROTONINERGIC SYSTEM
Deﬁcient serotonergic neurotransmission in various brain regions
is thought to be involved in the development of depression
and anxiety disorders (Nordquist and Oreland, 2010). In the
1950s, the ﬁndings that imipramine, a tricyclic compound, and
iproniazid, and antituberculosis drug, were effective in depres-
sion and anxiety and the observation that both drugs cause
an elevation of extracellular monoamine levels by blocking
monoamine oxidase (MAO) or inhibiting the neuronal sero-
tonin and/or noradrenaline transporter led to the hypothesis
of a “monoamine deﬁciency” in affective disorders (Coppen,
1967).
Serotonin is involved in a variety of physiological and behav-
ioral functions such as mood, affect, learning, aggression, and
stress response (Ressler and Nemeroff, 2000; Strüder and Weicker,
2001a,b). It is a metabolite of l-tryptophan, converted to 5-
hydroxytryptophan (5-HTP) by the tryptophan hydroxylase,
and thereafter immediately decarboxylated to serotonin by the
aromatic l-amino acid decarboxylase (Strüder and Weicker,
2001a,b; Daubert and Condron, 2010). The serotonin transporter
(SERT; Figure 2A) is responsible for the cellular reuptake of
5-HT.
The development of the SSRIs represents an important advance
in the pharmacotherapy of psychiatric disorders (Baldwin et al.,
2010). SSRIs inhibit the reuptake of serotonin into the presy-
naptic nerve terminal, thereby increasing 5-HT concentrations
in the synaptic cleft and prolonging its activity at postsynap-
tic receptor sites. After several weeks of treatment with SSRIs, a
desensitizationof presynaptic 5HT1A receptorsmayoccur (Kinney
et al., 2000). The 5HT1A receptor is a somatodendritic autorecep-
tor. Its activation results in a decreased ﬁring activity along the
serotonergic axon with a consequent enhancement of the sero-
tonergic neurotransmission (Castro et al., 2003; Hensler, 2003).
From the development of the serotonin transporter knockoutmice
(Mathews et al., 2004) and the consequent alteration in the 5-
HT homeostasis we have learned, for example, that the density
of the 5-HT receptors may vary. 5HT1A and 5-HT2A receptors are
decreased,while 5-HT1C receptors show anup-regulation (Li et al.,
1999, 2003). Of the 18 serotonin receptor subtypes so far charac-
terized in the CNS (Raymond et al., 2001), the 1A, 2A, and 2C
subtypes are predominantly involved in the modulation of mood
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FIGURE 2 | (A) Schematic model of the serotonin transporter and the molecule structure of serotonin (5-HT). (B) Schematic model of the sigma-1 receptor and
molecule structure of the sigma-1 agonists (+)-N -allylnormetazocine and (+)-SKF-10,047.
and anxiety (Toth, 2003; van Oekelen et al., 2003). For example,
long-term ﬂuoxetine treatment modulates the cannabinoid type-1
receptor action through 5HT1A receptor-dependent mechanisms
(Mato et al., 2010).
Fluoxetine, a selective SSRIs inhibitor is also a modulator of
neurosteroidogenesis in the brain (Pinna et al., 2006). Early studies
by Steiner et al. (1995) and Su et al. (1997) found that ﬂuoxetine
alleviated many symptoms of premenstrual dysphoric disorder,
which speciﬁcally correlates with ovarian hormones, including
progesterone. Thus, in line with these observations, ﬂuoxetine,
besides inhibiting serotonin reuptake, increased brain levels of 3α,
5α-THP in ﬂuoxetine-treated rats (Uzunov et al., 1996) and in
CSF and plasma of ﬂuoxetine-treated depressed patients (Romeo
et al., 1998; Uzunova et al., 1998). Moreover, Grifﬁn and Mel-
lon (1999) demonstrated that ﬂuoxetine is able to increase 3α,
5α-THP production by increasing the reduction of its precursor
5α-dihydroprogesterone (5α-DHP) via a direct interference with
the 3α-hydroxysteroid oxidoreductase. Whereas 5α-DHP medi-
ates a genomic action and interacts with intracellular progesterone
receptors (Rupprecht and Holsboer, 1999), 3α, 5α-THP is a potent
positive allosteric modulator of GABAA receptor function (Puia
et al., 1990, 2003; Lambert et al., 2003). Therefore, itmay be argued
that the mere blockade of the 5-HT uptake by ﬂuoxetine might
not be sufﬁcient to explain its ability to counteract impulsiveness,
anxiety, panic, and mood disturbances. On the other hand, the
anxiolytic actions of ﬂuoxetine might be explained by its ability to
increase brain neurosteroid content which, in turn, can modulate
GABAergic neurotransmission.
SIGMA-1 RECEPTORS
Sigma receptors were ﬁrst described as a subclass of the opioid
receptors (Martin et al., 1976). Two different receptors have been
characterized, sigma-1 and sigma-2 receptors that display differ-
ent drug selectivity and molecular mass (Hellewell and Bowen,
1990).
Sigma-1 receptors have been studied in learning and mem-
ory processes, depression and anxiety, schizophrenia and drug
abuse (Figure 2B). They can bind various exogenous ligands of
quite different structural classes, and with different therapeutic
and pharmacological proﬁles (Cobos et al., 2008). The anxiolytic
activity of sigma-1 ligands was ﬁrst described in the conditioned
fear stress model, in which the sigma-1 agonist (+)-SKF-10,047
was able to ameliorate conditioned fear stress (Kamei et al., 1996).
Noda et al. (2000) reported that this effect was further enhanced
in association with NS.
Neurosteroids are considered the most probable candidates as
endogenous ligands of the sigma-1 receptor (for a comprehen-
sive review see Monnet and Maurice, 2006). Cross pharmacology
between NS and sigma ligands has been reported and the anti-
depressant/anxiolytic action of NS can be antagonized by sigma
ligands. Su et al. (1988) ﬁrst described the ability of steroids, in
particular progesterone, to inhibit sigma receptor binding in brain
and spleen homogenates. Speciﬁcally, while pregnenolone, dehy-
droepiandrosterone (DHEA) and their sulfate esters act as agonists
of the sigma-1 receptors, progesterone acts as a potent antagonist
(Monnet et al., 1995; Bergeron and Debonnel, 1997; Maurice and
Privat, 1997). Pregnenolone sulfate and DHEA sulfate, but not
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pregnenolone and DHEA, were able to attenuate the conditioned
fear stress response in a dose-dependent manner in mice similar to
the putative sigma-1 receptor agonist, (+)-N -allylnormetazocine
(+)-SKF-10,047 (Noda et al., 2000). These effects were all attenu-
ated by the sigma-1 antagonist NE-100. Phan et al. (1999) have
demonstrated that endogenous NS, in particular progesterone,
can directly modulate sigma-related behavior. In particular, the
efﬁcacy of sigma-1 receptor agonists is inversely correlated with
the concentration of endogenous progesterone.
An important aspect to consider is the concurrent modula-
tion of the hypothalamic-pituitary–adrenal (HPA) axis by NS and
sigma ligands, the biological system that has been most closely
linked to the stress response in mammals. HPA axis activity is con-
trolled by the amygdala and the hippocampus. Stressors acting on
the amygdala stimulate the hypothalamus and potentially the HPA
axis, which in turn results in cortisol production by the adrenal
gland. Cortisol binds to glucocorticoid and mineralocorticoid
receptors in the hippocampus and, through a negative feed-back
loop, suppresses hypothalamic activity, and restores homeostasis.
This negative feed-back is altered in depressed/anxious patients
with a consequent enhancement of HPA axis activity (Rybakowski
and Twardowska, 1999). Stress, in turn, has been implicated to be
involved in the onset and maintenance of psychiatric disorders.
Moreover, psychosocial stressors have been shown to be related to
the onset of anxious episodes. Indeed, the stress- or panic-induced
released of NS has been suggested as an endogenous homeostatic
mechanism for restoring normal activity of the HPA axis (Barbac-
cia et al., 1996; Tait et al., 2002). Naert et al. (2007) have shown
a positive modulation by DHEA, DHEA sulfate of the HPA axis,
which could be explained also by their interaction with sigma-1
receptors (van Broekhoven and Verkes, 2003). Thus, DHEA and
DHEAsulfate rapidly activate theHPAaxis through sigma-1 recep-
tors as well as GABAA and NMDA receptors which also control the
HPA axis activity (Whitnall, 1993).
GABAergic SYSTEM
γ-Aminobutyric acid is the most abundant inhibitory neurotrans-
mitter in the CNS (Figure 3A; Schousboe and Waagepetersen,
2007). GABAA receptors are one of the most important targets
for the treatment of anxiety symptoms, because reduced GABAA
receptor functionmay be related to the pathophysiology of anxiety
(Nikolaus et al., 2010).
Numerous compounds can potentiate the GABA action
through positive modulation of GABAA receptor function.
FIGURE 3 | Structure of the GABAA (A) and the NMDA (B) receptors.
Molecular structure of GABA, and NMDA. DHEA sulphate and pregnenolone
sulphate as positive NMDA receptor modulators, and the SERT inhibitor
ﬂuoxetine. Fluoxetine has been shown to increase the brain and cerebrospinal
ﬂuid content of 3α, 5αTHP, a potent positive allosteric GABAA receptor
modulator.
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GABAA agonists, such as BDZs, are widely used for the acute
treatment of anxiety symptoms, such as panic, agitation, tension,
hyperarousal, sensation of lack of control, phobia, insomnia, since
they exert their efﬁcacy much more quickly than SSRIs (Ravindran
and Stein, 2010).
Barbiturates are GABAA agonists as well and have been used in
the past in view of their anticonvulsant, anxiolytic, sedative, and
hypnotic actions. However, due to their serious side effects, such
as a profound depression of CNS activity with the induction of
pronounced sedation and a lethal risk in case of overdose, they are
considered obsolete for the treatment of anxiety disorders (Smith
and Riskin, 1991).
Neurosteroids, in particular 3α, 5α-THP, represent the most
potent endogenous positive allosteric modulator of GABAA recep-
tors, with a BDZ- and barbiturates-like action (Belelli and Gee,
1989; Belelli et al., 1990; Lambert et al., 1995). When administered
systemically, 3α, 5α-THP possesses anxiolytic and anticonvulsant
properties and at the highest doses, sedative and hypnotic actions,
similar to those elicited byotherGABAA receptor agonists (Majew-
ska, 1992). The potency of NS atGABAA receptors shows a positive
correlation with their behavioral potencies (Kokate et al., 1994).
A plethora of behavioral and electrophysiological evidence sub-
stantiates the hypothesis that brain 3α, 5α-THP is a physiological
modulator of GABA with permissive action at GABAA receptors
amplifying the GABA gating of Cl-channels and increasing the
frequency and/or duration of openings of the channel (Puia et al.,
1990, 2003; Pinna et al., 2000; Dong et al., 2001). Moreover, con-
centrations in the micromolar range of this NS have been shown
to exert a certain intrinsic agonistic activity even in the absence
of GABA (Puia et al., 1990). Also the isomer 3α, 5β-THP exerts
a comparable positive modulation of GABAA receptors (Baulieu
et al., 2001).
3α, 5α-THP and its isomer bind to speciﬁc high afﬁnity sites
expressed on GABAA receptors, which differ from that of BDZs.
While pharmacological activities of BDZs at GABA-gated ion
channels vary with the α-subunit composition and require the
presence of a γ-subunit, such strictly deﬁned prerequisites are not
necessary for the actions of NS. Indeed, NS have high afﬁnity for
different GABAA receptors subtypes, in particular 3α, 5α-THP is
equipotent in facilitating the action of GABA on GABAA receptor
subtypes that are either homo-oligomeric (expressing only β sub-
units) or heteromeric (expressing α and β or α, β, and γ subunits;
Puia et al., 1990; Costa and Guidotti, 1996).
Numerous studies concerning the structure–activity relation-
ship of NS at GABA receptors revealed a stereoselectivity and the
presence of a 3α-hydroxy group of steroids within the A-ring of
thesemolecules as a critical determinant for their positive allosteric
activity at GABAA receptors (Gee et al., 1988; Blackmore et al.,
1994; El-Etr et al., 1998).
Reduced-NS concentrations have been reported during exper-
imental panic induction with either CCK-4 or sodium lactate
in patients with panic disorders but not in normal subjects,
suggesting a decrease of the GABAergic tone during experi-
mentally induced panic attacks in patients with panic disor-
der (Strohle et al., 2003). On the other hand, increased 3α-
reduced-NS plasma concentrations have been found in panic
disorder patients in the absence of panic attacks (Strohle et al.,
2002; Brambilla et al., 2003), suggesting that a greater GABA
receptor-mediated neuronal activity might represent a compen-
satory mechanism against the occurrence of spontaneous panic
attacks.
Endogenous NS can mediate the actions of alcohol at GABAA
receptors. Indeed, alcohol administration increases the concen-
tration of NS in the brain (Barbaccia et al., 1999). Alcohol with-
drawal symptoms in rats are alleviated by NS (Finn et al., 1995).
Moreover, plasma levels of NS are markedly reduced in alcoholic
patients during the early withdrawal phase, which is accompanied
by increased anxiety and depression scores (Romeo et al., 1996).
Interestingly, it has been shown that 3α, 5α-THP can promote
spontaneous GABA release at the GnRH-producing neurons, sug-
gesting a role in the control of gonadal steroid production and
secretion (Haage et al., 2002).
Pharmacological strategies for the treatment of anxiety are not
completely satisfying so far. BDZs offer the clear advantage of
being safer and better tolerated than barbiturates (i.e., low toxicity
comparedwith the life-threatening barbiturate toxicity). However,
there is still abuse potential for these drugs,which is a considerable
problem. Besides the abuse, also the well known tolerance liability
(reduction in the potency of BDZs) as well as amnesia and seda-
tion represent important side effects of BDZs. Therefore, chronic
treatment with BDZs is not recommended according to current
guidelines (Licata and Rowlett, 2008).
On the other hand, it has been shown that tolerance toward
anxiolytic effects is not developed by the GABAA receptor modu-
lating NS pregnanolone with intermittent chronic dosing (Kokate
et al., 1994). Therefore, neurosteroidogenic agents that lack BDZ-
like side effects may be a promising strategy in the treatment of
anxiety.
Indeed, NS replacement is a potential therapeutic approach,
but natural NS have poor bioavailability and may be converted to
metabolites with undesired progestational activity. The synthetic
NS ganaxolone (3alpha-hydroxy-3beta-methyl-5alpha-pregnane-
20-one) is an orally active analog of 3α, 5α-THP that is not
converted to the hormonally active 3-keto form. Because of its
longer duration of action, ganaxolonemight have greater tolerance
liability. However, clinical trials with ganaxolone in the treatment
of epilepsy have been encouraging and suggest that this NS has a
lower propensity for tolerance than BDZs (Reddy, 2010).
Moreover, an alternative to ganaxolone could be the use of
drugs that stimulate NS biosynthesis. One of these are ligands of
the translocator protein (18KDa), formerly called mitochondrial
BDZ receptor, such as indoleacetamide derivatives (Romeo et al.,
1992; Auta et al., 1993). Furthermore, drugs acting on the key
enzymes (i.e., 5α-reductase; 3α-hydroxysteroid oxidoreductase)
involved in the biosynthesis of 3α, 5α-THP, such as indomethacin,
ﬂuoxetine, and its congeners (SSRIs) are in part considered as
ﬁrst choice treatment for anxiety disorders (Romeo et al., 2000;
Guidotti et al., 2001; Pinna et al., 2004). Indeed, some of the
pharmacological actions of SSRIs may depend on their ability
to increase brain NS. Importantly, due to the brain region and
neuron-speciﬁc expression of the TSPO (18 kDa) and neuros-
teroidogenic enzymes, the impact of these drugs on NS biosyn-
thesis does not occur throughout the whole brain but is rather
region-speciﬁc. Therefore, SSRIs are devoid of certain unwanted
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side effects caused by direct systemic administration of NS (Pinna
et al., 2006).
GLUTAMATE
Anxiety-related disorders are frequently treated with drugs that
target the γ-aminobutyric acid or the serotonergic system. BDZs
and SSRI are the most widely prescribed treatments of these
disorders (Westenberg, 2009). A growing body of evidence sug-
gests that glutamatergic neurotransmission may also be involved
in the biological mechanisms underlying stress response and
anxiety-related disorders.
It is well established that NS regulate gene expression (genomic
effect) and can alter neuronal excitability by interacting with
speciﬁc neurotransmitter receptors (Rupprecht and Holsboer,
1999). While 3α, 5α-THP binds to GABAA receptors thereby
increasing the time and frequency of the opening of the Cl-
channel (Majewska et al., 1986), pregnenolone sulfate (PREGS)
has been described as both a positive NMDA receptor mod-
ulator (Figure 3B; Kussius et al., 2009) and negative GABAA
receptor modulator (Mtchedlishvili and Kapur, 2003). Behavioral
studies have shown that the increase of progesterone or prog-
esterone metabolites (such as 3α, 5α-THP) in proestrus female
rats increases the anxiolytic proﬁle in anxiety tests such as the
elevated place maze or the open ﬁeld test (Frye et al., 2000). In
addiction, systemically injected 3α, 5α-THP showed an anxiolytic
proﬁle similar to benzodiazepines or barbiturates in the mirrored
chamber test in mice (Reddy and Kulkarni, 1997). Thus, NS that
act as positive allostericmodulators of GABAA receptors have been
described as anxiolytic, sedative, and anticonvulsive substances
(Smith, 2002). On the other hand, systemically administered
PREGS showed a biphasic effect on anxiety responses depend-
ing on the dosage applied in different behavioral tests (Melchior
and Ritzmann, 1994; Reddy and Kulkarni, 1997).
TRANSLOCATOR PROTEIN
The TSPO (18KDa), formerly known as the peripheral or mito-
chondrial benzodiazepine receptor, is the cholesterol carrier from
the outer to the inner mitochondrial membrane, which is the
rate-limiting step of steroidogenesis (Krueger and Papadopoulos,
1990; Batarseh and Papadopoulos, 2010; Rupprecht et al., 2010).
Following cholesterol translocation, pregnenolone, and ring A-
reduced neurosteroids are synthesized,which in turn may enhance
GABA-mediated neurotransmission (Rupprecht and Holsboer,
1999; Rupprecht et al., 2010). Thus enhancing neurosteroidogene-
sis, via TSPO ligands may represent a new strategy in the treatment
of anxiety (for a recent review Rupprecht et al., 2010; Nothdurfter
et al., 2011). A decrease in TSPO expression on platelets or on
lymphocytes has been demonstrated in several anxiety disorders,
such as generalized anxiety disorder (Ferrarese et al., 1990; Rocca
et al., 1991), generalized social phobia (Johnson et al., 1998), panic
disorder (Marazziti et al., 1994), adult separation anxiety disor-
der (Chelli et al., 2008), and posttraumatic stress disorder (Gavish
et al., 1996).
In line with these observations, some TSPO ligands have been
shown to exert acute anxiolytic/anticonﬂict activity in rodent
models. Serra et al. (1999) have shown that the selective TSPO
ligands such as the 2-phenyl-imidazo[1,2-a]pyridine derivatives
(CB 34, CB 50, and CB 54) were able to increase the brain
concentrations of pregnenolone, progesterone, 3α, 5α-THP and
allotetrahydrodeoxycorticosterone (3α, 5α-THDOC) and that this
increase was associated with a marked anticonﬂict effect in the
Vogel test. More recently, Verleye et al. (2005) described a positive
interaction of etifoxine, a molecule with anxiolytic-like properties
in rodents (Verleye and Gillardin, 2004), which is also effective
in the treatment of adjustment disorder with anxiety in humans
(Servant et al., 1998). In membrane preparations from intact
male rat forebrain, they demonstrated that etifoxine uncompet-
itively inhibited the binding of the TSPO ligand PK11195. More-
over, in adrenalectomized-castrated (ADX-CX) rats receiving an
anxiolytic-like effective dose of etifoxine increased concentra-
tions of pregnenolone, progesterone, 5α-DHP and 3α, 5α-THP in
plasma and brain of sham-operated animals have been observed.
The authors concluded that following activation of TSPO in the
brain, an increased cerebral production of 3α, 5α-THP may par-
tially contribute to the anxiolytic-like effects of etifoxine. Kita and
Furukawa (2008) investigated the anxiolytic-like effects of AC-
5216, a TSPO ligand, in the social interaction test in mice demon-
strating that the anxiolytic-like effects of AC-5216 require newly
synthesized neurosteroids. Recently the TSPO ligand XBD173
(AC-5216) has indeed been shown to potentiate GABA-mediated
neurotransmission in mouse neocortical slices (Rupprecht et al.,
2009). This could be prevented by the 5α-reductase inhibitor
ﬁnasteride, which indicated that its action is mediated through
the generation of GABAergic NS. Furthermore, XBD173 counter-
acted CCK-4-induced panic in rodents and more importantly in
healthy male volunteers without showing BDZs-like side effects
(Rupprecht et al., 2009).
Thus, TSPO ligands may become promising therapeutic tools
for the treatment of anxiety-related disorders without the side
effects of other GABAA enhancing drugs such as BDZs.
CONCLUSION
Neurosteroids are powerful modulators within the CNS and they
affect numerous neurophysiological processes. They exert their
action already at low concentrations and they may act on differ-
ent neurotransmitter pathways. Their ability to modulate different
pathways that also interact with each other makes them interest-
ing candidates for the pharmacotherapyof anxiety disorders, in the
case of comorbidity with other mental diseases such as mood dis-
orders. One goal may be the identiﬁcation of synthetic NS which
show robust anxiolytic-like activity in view of a clear separation
between anxiolytic-like effects and sedation/ataxia. The new drugs
should have good oral bioavailability. NS apparently have less
abuse potential than benzodiazepines. Decreased abuse liability
together with the lack of interaction with ethanol, might present a
potential advantage over currently available benzodiazepine anx-
iolytics. Moreover, TSPO ligands can promote the production of
steroids, restore neurosteroid-mediated neurotransmission in the
brain, and thus compensate for anxiety states. As TSPO levels have
been found to be reduced in patients affected by anxiety disorders,
the use of ligands to stimulate TSPO steroidogenesis can offer a
novel therapeutic strategy for the treatment of anxiety.
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